Holen Sie sich die Stockscreener-App
163.51
1.29%
2.09
Vorhandelsmarkt:
162.60
-0.91
-0.56%
Schlusskurs vom Vortag:
$161.42
Offen:
$158.45
24-Stunden-Volumen:
2.66M
Relative Volume:
0.89
Marktkapitalisierung:
$34.87B
Einnahmen:
$447.02M
Nettoeinkommen (Verlust:
$-1.18B
KGV:
-26.45
EPS:
-6.1812
Netto-Cashflow:
$-906.14M
1W Leistung:
-0.13%
1M Leistung:
-6.48%
6M Leistung:
+59.44%
1J Leistung:
+125.50%
1-Tages-Spanne:
$156.01
$164.62
1-Wochen-Bereich:
$156.01
$164.96
52-Wochen-Spanne:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Vergleichen Sie INSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
163.51 | 34.43B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.08 | 111.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.78 | 77.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
809.64 | 49.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
355.53 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
334.28 | 37.42B | 4.98B | 69.59M | 525.67M | 0.5197 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Fortgesetzt | Truist | Buy |
| 2025-12-04 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-20 | Eingeleitet | William Blair | Outperform |
| 2025-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Eingeleitet | Jefferies | Buy |
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
What are the risks of holding Insmed IncorporatedTrade Ideas & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Market Review: Is Insmed Incorporated stock a smart retirement pick2025 Performance Recap & Consistent Growth Equity Picks - baoquankhu1.vn
Insmed Inc (INSM US): Brinsupri on High Trajectory; Multiple Readouts to Make 2026 a Pivotal Year - Smartkarma
Aug Reactions: Does Capital Growth Mortgage Investors L P Preferred Security have strong EBITDA marginsPortfolio Return Summary & High Conviction Buy Zone Alerts - baoquankhu1.vn
Aug Closing: What are the risks of holding Insmed Incorporated2025 Growth vs Value & Reliable Entry Point Alerts - baoquankhu1.vn
Analyst weighs patent cliff risks against Insmed’s (INSM) growth story - MSN
Analyst Weighs Patent Cliff Risks Against Insmed's (INSM) Growth Story - Finviz
Analyst Weighs Patent Cliff Risks Against Insmed’s (INSM) Growth Story - Insider Monkey
Insmed sinks after brensocatib fails trial for sinus condition - MSN
Analysts’ Top Healthcare Picks: Insmed (INSM), Roche Holding AG (RHHVF) - The Globe and Mail
EULAV Asset Management Acquires Shares of 90,000 Insmed, Inc. $INSM - MarketBeat
Looking At Insmed's Recent Unusual Options Activity - Benzinga
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed IncorporatedINSM - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed IncorporatedINSM - PR Newswire
Nisa Investment Advisors LLC Acquires 8,261 Shares of Insmed, Inc. $INSM - MarketBeat
Aug Reactions: Can Insmed Incorporated expand into new markets2025 Price Action Summary & Short-Term High Return Strategies - baoquankhu1.vn
SG Americas Securities LLC Acquires 13,305 Shares of Insmed, Inc. $INSM - MarketBeat
Bank of America Securities Keeps Their Buy Rating on Insmed (INSM) - The Globe and Mail
Jobs Data: What is the long term forecast for Insmed Incorporated stockJuly 2025 Earnings & Safe Capital Allocation Plans - baoquankhu1.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: Establishment Labs Holdings (ESTA), Sarepta Therapeutics (SRPT) and Insmed (INSM) - The Globe and Mail
Insmed CEO William Lewis sells $3.2 million in shares By Investing.com - Investing.com South Africa
Insmed CEO William Lewis sells $3.2 million in shares - Investing.com
Insmed (NASDAQ:INSM) CEO William Lewis Sells 19,215 Shares - MarketBeat
Insmed (BIT:1INSM) Price Target Decreased by 14.88% to 185.76 - Nasdaq
Insmed Insider Sold Shares Worth $351,341, According to a Recent SEC Filing - marketscreener.com
INSMED Chair and CEO William Lewis Sells 19,215 Shares - TradingView — Track All Markets
Short Squeeze: How Insmed Incorporated stock performs after earningsWeekly Risk Summary & Safe Entry Zone Tips - moha.gov.vn
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake - MSN
INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced - sharewise.com
Insmed Stock Pre-Market (+4.3%): Upbeat Analyst Day Highlights Strong BRINSUPRI™ Uptake & Pipeline - Trefis
MACD Signal: How Insmed Incorporated (IM8N) stock correlates with oil marketsTrade Entry Report & Smart Investment Allocation Insights - Bộ Nội Vụ
Rally Mode: Will Insmed Incorporated stock hit new highs in YEARQuarterly Performance Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Insmed stock soars as Brinsupri sales beat expectations by 116% - Investing.com Canada
Assessing Insmed (INSM) Valuation After Strong Multi‑Year Returns And Recent Share Price Pullback - simplywall.st
Top Pharmaceutical Stocks To Follow TodayJanuary 11th - MarketBeat
Insmed (INSM) Stock Undervalued by 54.3% Based on DCF Analysis - Intellectia AI
Is It Too Late To Reassess Insmed (INSM) After Its Huge Share Price Surge? - Yahoo Finance
The Bull Case For Insmed (INSM) Could Change Following Bold 2025 Revenue Guidance HikeLearn Why - Yahoo Finance
What risks investors should watch in Insmed Incorporated stockJuly 2025 Momentum & Low Volatility Stock Suggestions - ulpravda.ru
Tangible book value per share of Insmed Incorporated – BX:IM8N - TradingView — Track All Markets
Jim Cramer on Insmed: "This one is worth keeping an eye on" - MSN
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 - Reuters
Insmed (INSM) Surpasses Revenue Expectations with Strong Growth - GuruFocus
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal - BioPharma Dive
Insmed (NASDAQ:INSM) Shares Gap UpStill a Buy? - MarketBeat
Insmed Maps Aggressive 2026: New Lung Disease Drug, Pipeline AdvancesInsmed (NASDAQ:INSM) - Benzinga
Insmed posts early 2025 revenue beating consensus (INSM:NASDAQ) - Seeking Alpha
Insmed Jumps on ‘Blowout’ Sales Beat for Bronchiectasis Drug Brinsupri - BioSpace
Insmed: Strong Brinsupri Launch, Solid Arikayce Performance, and 2026 Catalysts Underpin Buy Rating - TipRanks
Insmed jumps after forecasting preliminary 2025 revenue above estimates - TradingView — Track All Markets
Insmed Incorporated Provides Revenue Guidance for the Full Year 2025 - marketscreener.com
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):